# Evaluation of N1539 Following Major Surgery

> **NCT02720692** · PHASE3 · COMPLETED · sponsor: **Baudax Bio** · enrollment: 722 (actual)

## Conditions studied

- Pain, Post-operative

## Interventions

- **DRUG:** N1539
- **DRUG:** Intravenous Placebo

## Key facts

- **NCT ID:** NCT02720692
- **Lead sponsor:** Baudax Bio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03
- **Primary completion:** 2017-03
- **Final completion:** 2017-05
- **Target enrollment:** 722 (ACTUAL)
- **Last updated:** 2023-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02720692

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02720692, "Evaluation of N1539 Following Major Surgery". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02720692. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*